Drug Trial Radar · NCT06034002
A Study to Evaluate INCA033989 Administered as a Monotherapy or in Combination With Ruxolitinib in Participants With Myeloproliferative Neoplasms
Last checked: Nov 19, 2026Latest source record: Apr 17, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
290
Planned (sponsor's estimate)
Start
Dec 4, 2023
Primary completion
Oct 29, 2028
Study completion Oct 29, 2028
Sponsor
- Lead sponsor
- Incyte CorporationIncyte (INCY)
- Sponsor type
- Industry
- First posted
- Sep 13, 2023
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study is being conducted to evaluate the safety, tolerability, dose-limiting toxicity (DLT) and determine the maximum tolerated dose (MTD) and/or recommended dose(s) for expansion (RDE) of INCA033989 administered as a Monotherapy or in Combination With Ruxolitinib in participants with myeloproliferative neoplasms.
Conditions
- Myeloproliferative Neoplasms
Interventions
INCA033989Drug
INCA033989 will be administered at protocol defined dose.
RuxolitinibDrug
Rux will be administered according to Prescribing Information/SmPC.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of participants with Dose Limiting Toxicities (DLTs)Time frame: Up to 28 days
- Number of participants with Treatment-emergent Adverse Events (TEAEs)Time frame: Up to 3 years and 60 days
Locations
13 sites in 1 country. Site status is shown where the registry gives one.
City of Hope Medical Center
Duarte, California · Recruiting
Stanford Cancer Institute
Palo Alto, California · Recruiting
University of Miami Health System
Miami, Florida · Recruiting
The University of Kansas Cancer Center
Westwood, Kansas · Recruiting
Johns Hopkins Hospital
Baltimore, Maryland · Recruiting
Dana Farber Cancer Institute
Boston, Massachusetts · Recruiting
Washington University School of Medicine
St Louis, Missouri · Recruiting
Icahn School of Medicine At Mount Sinai
New York, New York · Recruiting
Memorial Sloan Kettering Cancer Center
New York, New York · Recruiting
Wake Forest Baptist Medical Center
Winston-Salem, North Carolina · Recruiting
Cleveland Clinic
Cleveland, Ohio · Recruiting
Vanderbilt University Medical Center
Nashville, Tennessee · Recruiting
Md Anderson Cancer Center
Houston, Texas · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.